Condition: Breast Cancer Metastatic Breast Cancer · HER2-negative Breast Cancer · Sponsor: H. Lee Moffitt Cancer Center and Research Institute
This is a pilot study to determine feasibility and safety of the combination of Dendritic Cell (DC1) vaccines and elacestrant in patients with hormone positive HER2 negative metastatic breast cancer.
This description comes directly from the study's public registry record.
Taylor Lewis Whann · 813-745-0824 · Taylor.LewisWhann@moffitt.org
Aixa Soyano Muller, MD · Aixa.Soyano@moffitt.org
Always discuss trial participation with your own doctor first.
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06691035